

A Novel Metabolite of *Cinnamomum burmani*Yang TL¹, Yeh HC², Li HT³, Liu SL⁴ and Chen CY^{2*}

¹Department of Clinical Microbiology Laboratory, Yuan's General Hospital, Kaohsiung, Taiwan.

²School of Medical and Health Sciences, Fooyin University, 83102, Kaohsiung, Taiwan

³Department of Medical Laboratory Science and Biotechnology, Fooyin University, Kaohsiung 83102, Taiwan.

⁴Experimental Forest College of Bioresources and Agriculture, National Taiwan University, No.12, Sec. 1, Qianshan Rd., Zhushan Township, Nantou County, Taiwan (R.O.C.).

***Correspondence:**

Chen CY, School of Medical and Health Sciences, Fooyin University, 83102, Kaohsiung, Taiwan.

Received: 09 Dec 2023; Accepted: 12 Jan 2024; Published: 18 Jan 2024

Citation: Yang TL, Yeh HC, Li HT, et al. A Novel Metabolite of *Cinnamomum burmani*. Chem Pharm Res. 2024; 6(1): 1-5.

ABSTRACT

A new metabolite, burmanoside (**1**) was isolated from the plant flowers of *Cinnamomum burmani* (Nees & T. Nees) Blume (Lauraceae). The structure of **1** as a novel dioxane and tetrahydro-2H-pyran-3,4,5-triol skeleton. This structure was elucidated on the basis of physical and spectral analysis.

Keywords

Cinnamomum burmani, burmanoside, plant flowers, dioxane, tetrahydro-2H-pyran-3,4,5-triol.

Introduction

Cinnamomum burmani (Nees & T. Nees) Blume (Lauraceae) is a source of Indonesia cinnamon, and is widely used as a spice in Indonesia [1]. The chemical constituents of the roots of this plant have not yet been reported. Recently, we reported a new amide, a novel homosesquiterpenoid, along with five known amides from the stems of *C. burmani* [2,3]. Previously, we isolated 20 compounds, including one apocarotenoid, one triterpenoid, one coumarin, two steroids, and four benzenoids from the leaves of this plant [4,5]. In the course of screening for biologically and chemically novel agents from Formosan plants in the family Lauraceae [6-91], *C. burmani* was chosen for further phytochemical investigation. In this paper, we report the isolation and structural elucidation of this new metabolite (burmanoside (**1**)).

Compound **1**, obtained as colorless crystals, had the molecular formula C₁₄H₂₆O₁₁, as determined by HR-ESI-MS data (*m/z* 393.1377 ([M+Na]⁺; calc. 393.1373)) in combination with its ¹H-NMR, ¹³C-NMR and DEPT, requiring 2 degree of unsaturation. The IR spectrum show absorptions for hydroxyl group (3400 cm⁻¹)

¹). The ¹H- and ¹³C-NMR spectra indicated ten OCH, two CH₂, and two Me groups. In the ¹H-NMR spectrum, there were typical signals for two OMe groups at δ_H 3.44 (3H, s, OMe-14), and 3.58 (3H, s, OMe-15), two hydroxymethyl moieties at δ_H 4.37 (2H, d, *J* = 10.0 Hz, H-6) & 4.38 (2H, d, *J* = 10.8 Hz, H-13), ten oxymethines signals overlapping between δ_H 4.01~5.16 corroborated by ¹³C-NMR signals in Table 1 and were clarified and assigned based on COSY, NOESY (Figure 1), HSQC and HMBC (Table 1) spectra to confirm the existence of one dioxane and tetrahydro-2H-pyran-3,4,5-triol skeleton (Table 1). The HMBC correlations of H-4 (δ_H 4.39) to C-8 (δ_C 70.7), and H-8 (δ_H 4.52) to C-4 (δ_C 70.2) (Table 1) showed that the two moieties were bonded to C-4 and 8 by C-7, respectively. Two methoxyl groups δ_H 3.44 and 3.58 located at the C-1 and C-2 were determined by ¹³C-NMR signals (δ 106.0 and 101.4) and the HMBC correlation of OMe-14/C-1 and OMe-15/C-2. The attachment of two OMe substituents at C-1 and C-2 were confirmed by the correlation between OMe-14/H-1, OMe-15/H-2 and OMe-14/OMe-15 in NOESY spectrum. The full assignment of **1** was further confirmed by COSY, HSQC, and HMBC spectra.

The assignments were further verified by significant NOE correlations (Figure 1) and further supported the relative configuration of each substituents on the **1**. The ¹H- and ¹³C-NMR (Table 1), COSY,

NOESY (Figure 1), HSQC and HMBC (Table 1) experiments confirmed the structure as ((8*S**,9*R**,10*S**,11*R**,12*S**)-8-((*S**)-hydroxy((1*S**,2*R**,4*S**,5*R**)-4-(hydroxymethyl)-1,2-dimethoxy-3,6-dioxan-5-yl)methyl)-12-(hydroxymethyl)tetrahydro-2*H*-pyran-9,10,11-triol and designated as burmanoside (1).




Figure 1: Structure of compound 1 & major NOESY (H↔H) correlations of 1.

Table 1: ¹³C (Py-d₃) and ¹H HMR (Py-d₃) data of 1.

No	δ _c	δ _H	mult., J (Hz)	HMBC (¹ H → ¹³ C)
1	106.0	5.16	d, 4.0	C-2, C-14
2	101.4	4.63	d, 4.0	C-1, C-15
4	70.2	4.39	t, 6.8	C-5, C-6, C-7, C-8
5	72.2	4.26	td, 10.0, 6.8	C-4, C-6, C-7
6	62.4	4.37	d, 10.0	C-4, C-5
7	70.0	4.47	d, 6.8	C-4, C-5, C-8, C-9
8	70.7	4.52	d, 6.8	C-4, C-7, C-9, C-10
9	71.4	4.48	d, 6.8	C-7, C-8, C-10, C-11
10	72.3	4.41	d, 6.8	C-8, C-9, C-11, C-12
11	76.6	4.01	t-like, 6.8	C-9, C-10, C-12, C-13
12	75.0	4.22	td, 10.8, 6.8	C-10, C-11, C-13
13	62.1	4.38	d, 10.8	C-11, C-12
14	55.0	3.44	s	C-1
15	56.5	3.58	s	C-2

Experimental General

IR spectra were measured on a Hitachi 260-30 spectrophotometer. ¹H NMR (400 MHz, Py-d₃) and 2D spectra were obtained on Varian-Mercury-400 spectrometers. Low-resolution ESI-MS spectra were obtained on an API 3000 (Applied Biosystems) and high-resolution ESI-MS spectra on a Bruker Daltonics APEX II 30e spectrometer. Silica gel 60 (Merck, 70–230 mesh, 230–400 mesh) was used for column chromatography. Precoated Silica gel plates (Merck, Kieselgel 60 F-254), 0.20 mm and 0.50 mm, were used for analytical TLC and preparative TLC, respectively, visualized with 50% H₂SO₄.

Plant Material

The flowers of *C. burmani* (Nees & T. Nees) Blume were collected

from Nantou County, Taiwan, in June 2020. Plant material was identified by Dr. Su-Ling Liu (Experimental Forest College of Bioresources and Agriculture, National Taiwan University). A voucher specimen was deposited at the Department of Medical Technology, School of Medical and Health Sciences, Fooyin University, Kaohsiung, Taiwan.

Extraction and Isolation

The plant flowers (304 g) of *C. burmani* were air-dried and extracted repeatedly with MeOH (2 L × 5) at room temperature. The combined MeOH extracts (22.4 g) were then evaporated and further separated into 6 fractions by column chromatography on silica gel (4.5 kg, 70–230 mesh) with gradients of *n*-hexane/CH₂Cl₂/acetone/MeOH. Part of fraction 1 (3.5 g) was subjected to silica gel chromatography by eluting with *n*-hexane–acetone (70:1) enriched with acetone to furnish three further fractions (1-1–1-3). Fraction 1-1 (2.8 g) was further purified on a silica gel column using *n*-hexane–acetone mixtures to obtain 5-hydroxy-4,7-dimethoxyflavonoid (13 mg). Part of fraction 1-3 (2.3 g) was subjected to silica gel chromatography by eluting with *n*-hexane–acetone (50:1) enriched gradually with acetone to furnish five fractions (1-3-1–1-3-5). Fraction 1-3-2 (0.9 g) was further purified on a silica gel column using *n*-hexane–acetone mixtures to yield luteolin-7,3,4-trimethyl ether (4 mg) and 5,3-dihydroxy-7,4-dimethoxy-flavone (2 mg). Part of fraction 2 (2.1 g) was subjected to silica gel chromatography by eluting with *n*-hexane–acetone (40:1) enriched with acetone to furnish two further fractions (2-1–2-2). Fraction 2-1 (3.4 g) was further purified on a silica gel column using *n*-hexane–acetone mixtures to obtain persicogenin (11 mg) and genkwanin (14 mg). Part of fraction 3 (2.8 g) was subjected to silica gel chromatography by eluting with CH₂Cl₂–MeOH (100:1) enriched with MeOH to furnish five fractions (3-1–3-5). Fraction 3-3 (1.4 g) was further purified on a silica gel column using CH₂Cl₂–MeOH mixtures to obtain apigenin (7 mg) and luteolin (11 mg). Fraction 5 (3.8 g) eluted with *n*-hexane–EtOAc (1:1) was repeatedly subjected to silica gel CC and gave kaempferol (12 mg) and quercetin (16 mg). Part of fraction 6 (7.6 g) was subjected to silica gel chromatography by eluting with EtOAc–MeOH (20:1), enriched with MeOH to furnish five further fractions (6-1–6-5). Fraction 6-1 (3.2 g) was further purified on a silica gel column using *n*-hexane/acetone mixtures to obtain kaempferol 3-*O*-*L*-rhamnopyranoside (12 mg) and quercetin 3-*O*-*L*-rhamnopyranoside (9 mg). Fraction 6-3 (1.6 g) was further purified on a silica gel column using *n*-hexane/acetone mixtures to obtain burmanoside (1) (13 mg).

Burmanoside (1)

Colorless crystals. mp 194–196 °C. [α]_D²⁵ +12.5° (c 0.55, MeOH). IR (KBr, ν_{max}, cm⁻¹) ν_{max}: 3400 (OH) cm⁻¹. HR-EI-MS: *m/z* [M+Na]⁺ calcd for C₁₄H₂₆O₁₁Na: 393.1373; found: 393.1377. ¹H and ¹³C NMR (400 MHz, Py-d₃, δ, ppm, J/Hz): see Table 1.

Acknowledgment

This investigation was supported by grants from the Yuan's General Hospital (YGH-22-007).

References

1. Subehan, Kadota S, Tezuka Y. In vitro mechanism-based inactivation of cytochrome P450 3A4 by a new constituent of *Cinnamomum burmani*. *Planta Med.* 2008; 74: 1474-1480.
2. Hong ZL, Huang JC, Kuo SY, et al. Amides from the stems of *Cinnamomum burmannii*. *Nat Prod Commun.* 2011; 6: 1297-1298.
3. Chen CY, Hong ZL, Yang WL, et al. A novel homosesquiterpenoid from the stems of *Cinnamomum burmannii*. *Nat Prod Res.* 2012; 26: 1218-1223.
4. Li HT, Chen CH, Hong ZL, et al. Chemical constituents from the leaves of *Cinnamomum burmannii*. *Chem Nat Compd.* 2012; 48: 873-874.
5. Lin RJ, Kao CL, Liu SL, et al. A new apocarotenoid of *Cinnamomum burmannii*. *Chem Nat Compd.* 2020; 56: 604-606.
6. Chang YC, Chen CY, Chang FR, et al. Alkaloids from *Lindera glauca*. *J Chin Chem Soc.* 2001; 48: 811-815.
7. Chang FR, Hsieh TJ, Huang TL, et al. Cytotoxic constituents of the stem bark of *Neolitsea acuminatissima*. *J Nat Prod.* 2002; 65: 255-258.
8. Chen CY, Hsieh SL, Hsieh MM, et al. Substituent chemical shift of rhamnosides from the stem of *Cinnamomum osmophleum*. *Chin Pharm J.* 2004; 56: 141-146.
9. Chen CH, Lo WL, Liu YC, et al. Chemical and cytotoxic constituents from the leaves of *Cinnamomum kotoense*. *J Nat Prod.* 2006; 69: 927-933.
10. Hsieh TJ, Chen CH, Lo WL, et al. Lignans from the stems of *Cinnamomum camphora*. *Nat Prod Commun.* 2006; 1: 21-25.
11. Chen CY. Butanolides from the stems of *Cinnamomum kotoense*. *Nat Prod Commun.* 2006; 1: 453-455.
12. Chen CY, Chen CH, Wong CH, et al. Cytotoxic constituents of the stems of *Cinnamomum subavenium*. *J Nat Prod.* 2007; 70: 103-106.
13. Chen CY, Liu TZ, Chen CH, et al. Isoobtusilactone A-induces apoptosis in human hepatoma Hep G2 cells is mediated via increased NADPH oxidase-derived reactive oxygen species(ROS) production and the mitochondria-associated apoptotic mechanisms. *Food Chem Toxicol.* 2007; 45: 1268-1276.
14. Chen CY, Hsu YL, Chen YY, et al. Isokotomolide A, a new butanolide extracted from the leaves of *Cinnamomum kotoense*, arrests cell cycle progression and induces apoptosis through the induction of p53/p21 and the initiation of mitochondrial system in human non-small cell lung cancer A549 cells. *Eur J Pharmacol.* 2007; 574: 94-102.
15. Kuo PL, Chen CY, Hsu YL. Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells. *Cancer Res.* 2007; 67: 7406-7420.
16. Chen CY, Chen CH, Lo YC, et al. Anticancer activity of Isoobtusilactone A from *Cinnamomum kotoense*: involvement of apoptosis, cell-cycle dysregulation, mitochondria-regulation and reactive oxygen species. *J Nat Prod.* 2008; 71: 933-940.
17. Chen CY, Hsu YL, Tsai YC, et al. Kotomolide A arrests cell cycle progression and induces apoptosis through the induction of ATM/p53 and the initiation of mitochondrial system in human non-small cell lung cancer A549 cells. *Food Chem Toxicol.* 2008; 46: 2476-2484.
18. Kuo SY, Hsieh TJ, Wang YD, et al. Cytotoxic constituents from the leaves of *Cinnamomum subavenium*. *Chem Pharm Bull.* 2008; 56: 97-101.
19. Lin RJ, Lo WL, Wang YD, et al. A novel cytotoxic monoterpenoid from the leaves of *Cinnamomum subavenium*. *Nat Prod Res.* 2008; 22: 1055-1059.
20. Kuo PL, Chen CY, Tzeng TF, et al. Involvement of reactive oxygen species/c-Jun NH2-terminal kinase pathway in kotomolide A induces apoptosis in human breast cancer. *Toxicol Appl Pharm.* 2008; 229: 215-226.
21. Liu TZ, Cheng JT, Yiin SJ, et al. Isoobtusilactone A induces both caspase-dependent and-independent apoptosis in Hep G2 cells. *Food Chem Toxicol.* 2008; 46: 321-327.
22. Lin RJ, Cheng MJ, Huang JC, et al. Cytotoxic compounds from the stems of *Cinnamomum tenuifolium*. *J Nat Prod.* 2009; 72: 1816-1824.
23. Chen CY, Cheng MJ, Chiang YJ, et al. Chemical constituents from the leaves of *Machilus zuihoensis* Hayata var. *mushaensis* (Lu) Y. C. Liu. *Nat Prod Res.* 2009; 23: 871-875.
24. Chen CY, Yang WL, Hsui YR. A novel sesquiterpenoid from the roots of *Cinnamomum subavenium*. *Nat Prod Res.* 2010; 24: 423-427.
25. Cheng MJ, Lo WL, Tseng WS, et al. A novel normoterpenoid from the stems of *Cinnamomum reticulatum* Hay. *Nat Prod Res.* 2010; 24: 732-736.
26. Lin IJ, Lo WL, Chia YC, et al. Isolation of new esters from the stems of *Cinnamomum reticulatum* Hay. *Nat Prod Res.* 2010; 24: 775-780.
27. Cheng KC, Hsueh MC, Chang HC, et al. Antioxidants from the leaves of *Cinnamomum kotoense*. *Nat Prod Commun.* 2010; 5: 911-912.
28. Hsieh TJ, Hsieh SF, Chen CY. Chemical constituents from the stems of *Cinnamomum insulari-montanum*. *Chem Nat Compd.* 2010; 46: 99-100.
29. Chen CY, Wang HM, Chung SH, et al. Chemical constituents from the roots of *Cinnamomum subavenium*. *Chem Nat Compd.* 2010; 46: 474-476.
30. Chen CY, Wang YD, Wang CJ. Chemical constituents from the leaves of *Cinnamomum philippinense*. *Chem Nat Compd.* 2010; 46: 941-942.
31. Wang HM, Chiu CC, Wu PF, et al. Subamolide E from *Cinnamomum subavenium* induces cell cycle arrest, caspase-dependent apoptosis and reduced migration ability in human melanoma cells. *J Agric Food Chem.* 2011; 59: 8187-8192.

32. Shen KH, Lin ES, Kuo PL, et al. Isolinderanolide B, a butanolide extracted from the stems of *Cinnamomum subavenium*, inhibits proliferation of T24 human bladder cancer cells via blocking cell cycle progression and inducing apoptosis. *Integr Cancer Ther.* 2011; 10: 350-358.
33. Chen CY, Yeh HC. A new amide from the stems of *Cinnamomum reticulatum* Hay. *Nat Prod Res.* 2011; 25: 26-30.
34. Cheng MJ, Yeh YT, Wang CJ, et al. Isolation of a nitrobenzoate from the leaves of *Cinnamomum tenuifolium*. *Nat Prod Res.* 2011; 25: 118-122.
35. Lin IJ, Yeh HC, Cham TM, et al. A new butanolide from the leaves of *Cinnamomum reticulatum* Hayata. *Chem Nat Compd.* 2011; 47: 43-45.
36. Chen CY, Wang YD. A novel sesquiterpenoid from the leaves of *Cinnamomum subavenium*. *Chem Nat Compd.* 2011; 47: 215-217.
37. Chia YC, Yeh HC, Yeh YT, et al. Chemical constituents from the leaves of *Cinnamomum reticulatum* Hay. *Chem Nat Compd.* 2011; 47: 220-222.
38. Chen CY. Chemical constituents from the roots of *Cinnamomum reticulatum* Hayata. *Chem Nat Compd.* 2011; 47: 306-308.
39. Chen CY, Hong ZL. Chemical constituents from the fruits of *Cinnamomum kotoense*. *Chem Nat Compd.* 2011; 47: 450-451.
40. Chen CY, Wang YD. Norcadinane sesquiterpene from the roots of *Cinnamomum subavenium* Miq. *Chem Nat Compd.* 2011; 47: 461-462.
41. Chen CY, Yeh YT, Hsui YR. A new lignan from the roots of *Cinnamomum philippinense*. *Chem Nat Compd.* 2011; 47: 519-520.
42. Yang WL, Guo YC, Lin HH, et al. Chemical constituents from the twigs of *Cinnamomum macrostemon* Hayata. *Chem Nat Compd.* 2011; 47: 1030-1031.
43. Wang HM, Chen CY, Wen ZH. Identifying melanogenesis inhibitors by targeting the human tyrosinase from *Cinnamomum subavenium* with in vitro and in vivo screening systems. *Exp Dermatol.* 2011; 20: 242-248.
44. Liu CH, Chen CY, Huang AM, et al. Subamolide A, a component isolated from *Cinnamomum subavenium*, induces apoptosis mediated by mitochondria-dependent, p53 and ERK1/2 pathways in human urothelial carcinoma cell line NTUB1. *J Ethnopharmacol.* 2011; 137: 503-511.
45. Chen CY, Yiin SJ, Hsu JL, et al. Isoobtusilactone A sensitizes human hepatoma Hep G2 cells to TRAIL-induced apoptosis via ROS and CHOP-mediated up-regulation of DR5. *J Agric Food Chem.* 2012; 60: 3533-3539.
46. Li HT, Li WJ, Wu HM, et al. Alkaloids from *Cinnamomum philippinense*. *Nat Prod Commun.* 2012; 7: 1581-1582.
47. Cheng MJ, Yeh YT, Wang CJ, et al. A new 3,4-dihydronaphthalen-1(2H)-one from the leaves of *Cinnamomum philippinense*. *Nat Prod Res.* 2012; 26: 1433-1435.
48. Chen HL, Kuo SY, Li YP, et al. A new benzodioxocinone from the leaves of *Cinnamomum tenuifolium*. *Nat Prod Res.* 2012; 26: 1881-1886.
49. Cheng KC, Chen HA, Wu PF, et al. Three novel antioxidants from *Cinnamomum* plants. *Afr J Biotechnol.* 2012; 11: 4463-4466.
50. Chen HL, Yang WL, Li YP, et al. A novel homosesquiterpene from *Cinnamomum macrostemon* Hayata. *J Med Med Sci.* 2012; 3: 90-92.
51. Hung JY, Wen CW, Hsu YL, et al. Subamolide A induces mitotic catastrophe accompanied by apoptosis in human lung cancer cell. *Evid-based Complement Altern Med.* 2013; 2013: 1-15. Article ID 828143.
52. Yang SY, Wang HM, Wu TW, et al. Subamolide B induces cytotoxicity in human cutaneous squamous cell carcinoma cells through mitochondrial and endoplasmic reticulum stress cell death pathways. *Evid-based Complement Altern Med.* 2013; 2013: 1-13. Article ID 630415.
53. Lee CH, Kuo CN, Chen HL, et al. Review on pharmacological activities of *Cinnamomum subavenium*. *Nat Prod Res.* 2013; 27: 988-991.
54. Dong HP, Wu HM, Chen SJ, et al. The effect of butanolides from *Cinnamomum tenuifolium* on platelet aggregation. *Molecules.* 2013; 18: 11836-11841.
55. Lee CH, Liu CM, Li YP, et al. Review on pharmacological activities of *Cinnamomum reticulatum*. *Int J Curr Pharm Clin Res.* 2014; 4: 27-29.
56. Wang HM, Chen CY, Wu PF. Isophilippinolide A arrests cell cycle progression and induces apoptosis for anticancer inhibitory agents in human melanoma cells. *J Agric Food Chem.* 2014; 62: 1057-1065.
57. Liu CM, Kao CL, Chen SJ, et al. Pharmacological studies of isoobtusilactone A from *Cinnamomum kotoense* with anticancer potential. *J Nat Prod Plant Resour.* 2014; 4: 26-29.
58. Liu CM, Yeh HC, Huang SH, et al. The antioxidation and antiproliferation activity of new flavonoids from the leaves and stems of *Cinnamomum reticulatum* Hayata. *Med Chem.* 2015; 5: 64-66.
59. Li CT, Kao CL, Li HT, et al. Secondary metabolites from the leaves of *Cinnamomum macrostemon* Hayata. *Eur J Biomed Pharm Sci.* 2015; 2: 38-51.
60. Kao CL, Cho CL, Wu HM, et al. Cinnapine, a new pyridine alkaloid from *Cinnamomum philippinense*. *Chem Nat Compd.* 2015; 51: 736-738.
61. Hseu YC, Cheng KC, Lin YC, et al. Synergistic effects of linderanolide B combined with arbutin, PTU or kojic acid on tyrosinase inhibition. *Curr Pharm Biotechnol.* 2015; 16: 1120-1126.
62. Chen CY, Yen CY, Wang HM, et al. Tenuifolide B from *Cinnamomum tenuifolium* stem selectively inhibits proliferation of oral cancer cells via apoptosis, ROS generation, mitochondrial depolarization, and DNA damage. *Toxins.* 2016; 8: 319.

63. Li HT, Yeh HC, Chen CY. Secondary metabolites from the leaves of *Cinnamomum kanehirai* Hayata. *Chem Nat Compd.* 2016; 52: 1143-1144.
64. Yuan LT, Kao CL, Chen CT, et al. A new lignan from *Cinnamomum burmani*. *Chem Nat Compd.* 2017; 53: 623-625.
65. Lin YH, Chen CY, Chou LY, et al. Enchantment of bone marrow-derived mesenchymal stem cell osteogenesis and new bone formation in rats by obtusilactone A. *Int J Mol Sci.* 2017; 18: 2422.
66. Chen CY, Kao CL, Li WJ, et al. Secondary metabolites from the roots of *Cinnamomum macrostemon*. *Chem Nat Compd.* 2018; 54: 562-563.
67. Lin CL, Perng MH, Li WJ, et al. Chemical constituents of the roots of *Cinnamomum randaiense*. *Chem Nat Compd.* 2018; 54: 628-630.
68. Lin CL, Kao CL, Li WJ, et al. Secondary metabolites from the stems of *Cinnamomum kanehirai*. *Chem Nat Compd.* 2018; 54: 762-763.
69. Huang GC, Kao CL, Li WJ, et al. A new diphenyl ether from *Cinnamomum subavenium*. *Chem Nat Compd.* 2018; 54: 869-871.
70. Liu CM, Perng MH, Chen CY. Antioxidant activities of crude extracts from peel and seed of *Cinnamomum camphora*. *Biomed Res.* 2018; 29: 2854-2858.
71. Chen CY, Lin CL, Kao CL, et al. Chemical constituents of the leaves of *Cinnamomum insulari-montanum*. *Chem Nat Compd.* 2019; 55: 922-923.
72. Chen CT, Kao CL, Li WJ, et al. Secondary metabolites from the roots of *Cinnamomum kanehirae*. *Chem Nat Compd.* 2019; 55: 1185-1186.
73. Li J, Chen CY, Huang JY, et al. Isokotomolide A from *Cinnamomum kotoense* induce melanoma autophagy and apoptosis in vivo and in vitro. *Oxid Med Cell Longev.* 2020; 2020: 1-16. Article ID 3425147.
74. Chen CY, Chen CT, Liu SL, et al. A new dimeric lignan from *Machilus philippinensis*. *Chem Nat Compd.* 2020; 56: 611-613.
75. Chen CY, Liu CM, Wu HM, et al. A new pyrone from *Cinnamomum macrostemon*. *Chem Nat Compd.* 2020; 56: 621-622.
76. Liu SL, Yang KH, Yang CW, et al. Burmannic acid inhibits proliferation and induces oxidative stress response on oral cancer cells. *Antioxidants.* 2021; 10: 1588.
77. Chen CY, Kao CL, Yeh HC, et al. A novel cyclopropanoid from *Cinnamomum osmophleum*. *Chem Nat Compd.* 2021; 57: 848-850.
78. Liu SL, Kao CL, Yeh HC, et al. A new β -ionone from *Cinnamomum burmanni*. *Chem Nat Compd.* 2021; 57: 861-863.
79. Chen CY, Kao CL, Yeh HC, et al. A novel bibenzyl derivative of *Cinnamomum insulari-montanum*. *Chem Nat Compd.* 2022; 58: 18-20.
80. Chen CY, Kao CL, Yeh HC, et al. A novel biaryl ether from *Cinnamomum osmophleum*. *Chem Nat Compd.* 2022; 58: 793-795.
81. Chang CT, Kao CL, Yeh HC, et al. A new flavanone from *Cinnamomum subavenium*. *Chem Pharm Res.* 2022; 4: 1-3.
82. Chang CT, Liu CM, Yeh HC, et al. A new homosesquiterpenoid of *Cinnamomum macrostemon*. *Chem Pharm Res.* 2022; 4: 1-5.
83. Chang CT, Liu CM, Yeh HC, et al. Identification and antiviral activities of butanolide skeleton from *Cinnamomum kotoense* and *Cinnamomum subavenium* by inhibiting H5N1 neuraminidase. *Chem Pharm Res.* 2022; 4: 1-7.
84. Shih PK, Lee PY, Wang HM, et al. Antioxidant activity of *Cinnamomum osmophleum*. *Chem Nat Compd.* 2023; 59: 163-166.
85. Chen CY, Hsu LY, Liu CM, et al. A new homosesquiterpene from *Cinnamomum reticulatum*. *Chem Nat Compd.* 2023; 59: 282-284.
86. Chen CY, Liu CM, Yeh HC, et al. New metabolite from *Cinnamomum tenuifolium*. *Chem Nat Compd.* 2023; 59: 336-338.
87. Chen CY, Kao CL, Huang ST, et al. A new dimeric benzenoid of *Cinnamomum randaiense*. *Chem Nat Compd.* 2023; 59: 481-483.
88. Chen CY, Huang ST, Wang JJ, et al. A novel diaryl derivative from *Antrodia camphorata*. *Chem Nat Compd.* 2023; 59: 490-492.
89. Yang TL, Yeh HC, Li HT, et al. A new tetrahydrofuran of *Cinnamomum burmannii*. *Chem Pharm Res.* 2023; 5: 1-5.
90. Chen CY, Liu CM, Yeh HC, et al. Metabolites from *Cinnamomum subavenium* with anti-dengue virus activity. *Chem Nat Compd.* 2024; 60.
91. Chen CY, Li WJ, Li HT, et al. Anti-tumor activity of *Cinnamomum macrostemon*. *Chem Nat Compd.* 2024; 60.